Home » Newsletters » BioWorld Science

BioWorld Science

April 29, 2013

View Archived Issues

Chugai Pharmaceutical presents highlights of first quarter 2013

CAP37 as a potential new early biomarker of neuroinflammation

Ampio Pharmaceuticals completes enrollment in SPRING study of Ampion

Medgenics reports interim data from phase IIa study of Epodure Biopumps

Perosphere and Daiichi Sankyo enter trial agreement for PER-977

Researchers launch avert-AF initiative

Novel AXL kinase inhibitor TP-0903 inhibits pancreatic cell growth

AMG-747 demonstrates promising antipsychotic-like effects in vivo

Lixte Biotechnology commences first clinical trial of lead anticancer compound

R-Tech Ueno gains IND clearance from FDA for RU-101

Second phase III trial of DSC-127 commences in patients with diabetic foot ulcers

Afinitor filed for approval for breast cancer in Japan

Bristol-Myers Squibb offers overview of first quarter 2013

Researchers identify NS5A variants after IDX-719 treatment

First phase II results of cadazolid in patients with C. difficile-associated diarrhea reported

Merck & Co. discloses new PDE10A inhibitors

Researchers at Janus Biotherapeutics patent novel TLR9 antagonists

Revlimid receives positive CHMP opinion for myelodysplastic syndrome

Roche designs novel CRAC channel modulators

Bayer Intellectual Property presents novel BUB1 inhibitors

GSK files MAA seeking approval of umeclidinium as monotherapy for COPD

European CHMP recommends approval of avanafil for erectile dysfunction

EMA committee recommends approval of Xtandi

CHMP issues positive opinion for approval of Nuedexta

European CHMP recommends conditional approval of Erivedge for BCC

EMA's CHMP recommends restricting use of Protelos/Osseor

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Hits’ Hyperlab launches as ‘virtual AI lab’ for new drug discovery
BioWorld Science
Things once done in laboratories can now be done with computers and AI, said Kim Woo-youn, CEO and cofounder of Hits Inc. “We live in the age of ‘digital...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...